The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).

The present invention relates to antigen-binding molecules, including bispecific antigen-binding molecules that bind human GP130 and/or human leptin receptor (LEPR), and the use of such antigen-binding molecules for the treatment of conditions and disorders related to leptin deficiency or leptin resistance. The bispecific antigen-binding molecules of the present invention can be, e.g., bispecific antibodies comprising a first antigen-binding domain that specifically binds human GP130 and a second antigen-binding domain that specifically binds human LEPR. The bispecific antigen-binding molecules of the present invention are useful in therapeutic applications where induced leptin and/or LEPR-mediated signaling would be beneficial, e.g., in the treatment of obesity, lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.

The present invention relates to antigen-binding molecules, including bispecific antigen-binding molecules that bind human GP130 and/or human leptin receptor (LEPR), and the use of such antigen-binding molecules for the treatment of conditions and disorders related to leptin deficiency or leptin resistance. The bispecific antigen-binding molecules of the present invention can be, e.g., bispecific antibodies comprising a first antigen-binding domain that specifically binds human GP130 and a second antigen-binding domain that specifically binds human LEPR. The bispecific antigen-binding molecules of the present invention are useful in therapeutic applications where induced leptin and/or LEPR-mediated signaling would be beneficial, e.g., in the treatment of obesity, lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.

GHR-106 monoclonal antibody or antigen-binding fragments thereof are provided and used to modulate levels of reproductive hormones in vivo when administered to mammalian subjects. The GHR-106 monoclonal antibody or an antigen-binding fragment thereof can be used to control ovulation, terminate ectopic pregnancy, and/or treat reproductive disorders or conditions in mammalian subjects.

Combination of dry extract of Rhodiola, dry extract of Trubulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing.

Combination of dry extract of Rhodiola, dry extract of Trubulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing.

The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyl-oxy)-4-methoxyphenyl]-2,4-dioxo- 1,2,3,4-tetrahydrothieno [3 ,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.

The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyl-oxy)-4-methoxyphenyl]-2,4-dioxo- 1,2,3,4-tetrahydrothieno [3 ,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.

The invention provides compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists and uses thereof. Specifically, the invention provides polymer compositions and methods for controlled release of GnRH antagonists.

The invention provides compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists and uses thereof. Specifically, the invention provides polymer compositions and methods for controlled release of GnRH antagonists.